Summary of Study ST000410

This data is available at the NIH Common Fund's National Metabolomics Data Repository (NMDR) website, the Metabolomics Workbench, https://www.metabolomicsworkbench.org, where it has been assigned Project ID PR000320. The data can be accessed directly via it's Project DOI: 10.21228/M8MP4W This work is supported by NIH grant, U2C- DK119886.

See: https://www.metabolomicsworkbench.org/about/howtocite.php

Study ID	ST000410
Study Title	Metabolomic analysis of oxytocin effects on social deficits in mice (part III)
Study Summary	The goal of this study is to determine the prosocial hormone oxytocin (OT) effects on metabolomic profiles in brain.
Institute	University of North Carolina
Laboratory	Sumner Lab
Last Name	Sumner
First Name	Susan
Address	Eastern Regional Comprehensive Metabolomics Resource Core, UNC Nutrition Research Institute, 500 Laureate Way, Kannapolis, NC, 28081
Email	susan_sumner @unc.edu
Phone	704-250-5066
Submit Date	2016-06-17
Raw Data Available	Yes
Raw Data File Type(s)	cdf
Analysis Type Detail	NMR
Release Date	2017-07-10
Release Version	1

Select appropriate tab below to view additional metadata details:

Project:

Project ID:	PR000320
Project DOI:	doi: 10.21228/M8MP4W
Project Title:	Metabolomic analysis of oxytocin effects on social deficits in mice
Project Summary:	The goal of this study was to determine the effects of the neuropeptide oxytocin (OT) on metabolomic profiles, using a mouse model of autism-like behavior, the BALB/cByJ inbred strain. We have previously reported that subchronic treatment with OT can lead to persistent reversal of social deficits in BALB/cByJ and other models of autism spectrum disorder (ASD). In this study, mice were given a subchronic regimen with either vehicle or OT, and then evaluated for social approach. At the end of the study, brain and blood were collected for metabolomic analysis. In addition, fecal samples were taken at different time points during the treatment and testing regimen. The results from this project could elucidate mechanisms underlying the prosocial effects of oxytocin, and identify new targets for the development of highly specific oxytocin-related drugs.
Institute:	University of North Carolina at Chapel Hill
Department:	Department of Psychiatry
Last Name:	Moy
First Name:	Sheryl
Address:	CB# 7146, Chapel Hill, NC 277599
Email:	ssmoy@med.unc.edu
Phone:	919-966-3082

Subject:

Subject ID:	SU000431
Subject Type:	Mice
Subject Species:	Mus musculus
Taxonomy ID:	10090
Species Group:	Mammal

Factors:

Subject type: Mice; Subject species: Mus musculus (Factor headings shown in green)

mb_sample_id	local_sample_id	Treatment
SA020072	B_68	Oxytocin \| Brain region:Cerb
SA020073	B_70	Oxytocin \| Brain region:Cerb
SA020074	B_66	Oxytocin \| Brain region:Cerb
SA020075	B_65	Oxytocin \| Brain region:Cerb
SA020076	B_62	Oxytocin \| Brain region:Cerb
SA020077	B_72	Oxytocin \| Brain region:Cerb
SA020078	B_61	Oxytocin \| Brain region:Cerb
SA020079	B_63	Oxytocin \| Brain region:Cerb
SA020080	B_77	Oxytocin \| Brain region:Cerb
SA020081	B_79	Oxytocin \| Brain region:Cerb
SA020082	B_75	Oxytocin \| Brain region:Cerb
SA020083	B_74	Oxytocin \| Brain region:Cerb
SA020084	B_30	Oxytocin \| Brain region:Fore
SA020085	B_34	Oxytocin \| Brain region:Fore
SA020086	B_37	Oxytocin \| Brain region:Fore
SA020087	B_39	Oxytocin \| Brain region:Fore
SA020088	B_28	Oxytocin \| Brain region:Fore
SA020089	B_35	Oxytocin \| Brain region:Fore
SA020090	B_32	Oxytocin \| Brain region:Fore
SA020091	B_23	Oxytocin \| Brain region:Fore
SA020092	B_21	Oxytocin \| Brain region:Fore
SA020093	B_25	Oxytocin \| Brain region:Fore
SA020094	B_22	Oxytocin \| Brain region:Fore
SA020095	B_26	Oxytocin \| Brain region:Fore
SA020096	B_97	Oxytocin \| Brain region:Hind
SA020097	B_99	Oxytocin \| Brain region:Hind
SA020098	B_85	Oxytocin \| Brain region:Hind
SA020099	B_94	Oxytocin \| Brain region:Hind
SA020100	B_95	Oxytocin \| Brain region:Hind
SA020101	B_86	Oxytocin \| Brain region:Hind
SA020102	B_90	Oxytocin \| Brain region:Hind
SA020103	B_82	Oxytocin \| Brain region:Hind
SA020104	B_88	Oxytocin \| Brain region:Hind
SA020105	B_81	Oxytocin \| Brain region:Hind
SA020106	B_83	Oxytocin \| Brain region:Hind
SA020107	B_92	Oxytocin \| Brain region:Hind
SA020108	B_50	Oxytocin \| Brain region:Mid
SA020109	B_57	Oxytocin \| Brain region:Mid
SA020110	B_59	Oxytocin \| Brain region:Mid
SA020111	B_55	Oxytocin \| Brain region:Mid
SA020112	B_54	Oxytocin \| Brain region:Mid
SA020113	B_52	Oxytocin \| Brain region:Mid
SA020114	B_46	Oxytocin \| Brain region:Mid
SA020115	B_42	Oxytocin \| Brain region:Mid
SA020116	B_43	Oxytocin \| Brain region:Mid
SA020117	B_41	Oxytocin \| Brain region:Mid
SA020118	B_45	Oxytocin \| Brain region:Mid
SA020119	B_48	Oxytocin \| Brain region:Mid
SA020120	B_3	Oxytocin \| Brain region:OlF
SA020121	B_15	Oxytocin \| Brain region:OlF
SA020122	B_14	Oxytocin \| Brain region:OlF
SA020123	B_19	Oxytocin \| Brain region:OlF
SA020124	B_6	Oxytocin \| Brain region:OlF
SA020125	B_5	Oxytocin \| Brain region:OlF
SA020126	B_8	Oxytocin \| Brain region:OlF
SA020127	B_10	Oxytocin \| Brain region:OlF
SA020128	B_1	Oxytocin \| Brain region:OlF
SA020129	B_12	Oxytocin \| Brain region:OlF
SA020130	B_2	Oxytocin \| Brain region:OlF
SA020131	PB_3	Pool \| Brain region:Pool
SA020132	PB_2	Pool \| Brain region:Pool
SA020133	PB_4	Pool \| Brain region:Pool
SA020134	PB_1	Pool \| Brain region:Pool
SA020135	B_73	Veh \| Brain region:Cerb
SA020136	B_71	Veh \| Brain region:Cerb
SA020137	B_78	Veh \| Brain region:Cerb
SA020138	B_80	Veh \| Brain region:Cerb
SA020139	B_64	Veh \| Brain region:Cerb
SA020140	B_76	Veh \| Brain region:Cerb
SA020141	B_67	Veh \| Brain region:Cerb
SA020142	B_69	Veh \| Brain region:Cerb
SA020143	B_24	Veh \| Brain region:Fore
SA020144	B_38	Veh \| Brain region:Fore
SA020145	B_40	Veh \| Brain region:Fore
SA020146	B_27	Veh \| Brain region:Fore
SA020147	B_36	Veh \| Brain region:Fore
SA020148	B_29	Veh \| Brain region:Fore
SA020149	B_33	Veh \| Brain region:Fore
SA020150	B_31	Veh \| Brain region:Fore
SA020151	B_87	Veh \| Brain region:Hind
SA020152	B_89	Veh \| Brain region:Hind
SA020153	B_96	Veh \| Brain region:Hind
SA020154	B_100	Veh \| Brain region:Hind
SA020155	B_98	Veh \| Brain region:Hind
SA020156	B_93	Veh \| Brain region:Hind
SA020157	B_91	Veh \| Brain region:Hind
SA020158	B_84	Veh \| Brain region:Hind
SA020159	B_56	Veh \| Brain region:Mid
SA020160	B_51	Veh \| Brain region:Mid
SA020161	B_49	Veh \| Brain region:Mid
SA020162	B_44	Veh \| Brain region:Mid
SA020163	B_53	Veh \| Brain region:Mid
SA020164	B_47	Veh \| Brain region:Mid
SA020165	B_58	Veh \| Brain region:Mid
SA020166	B_60	Veh \| Brain region:Mid
SA020167	B_16	Veh \| Brain region:OlF
SA020168	B_11	Veh \| Brain region:OlF
SA020169	B_18	Veh \| Brain region:OlF
SA020170	B_13	Veh \| Brain region:OlF
SA020171	B_4	Veh \| Brain region:OlF

Showing page 1 of 2 Results: 1 2 Next Showing results 1 to 100 of 103

Collection:

Collection ID:	CO000425
Collection Summary:	24 hr after the social test, mice were deeply anesthetized with 5% isoflurane, followed by rapid decapitation. Brains were removed, rinsed with ice-cold water, and then rapidly dissected into the following 5 regions: forebrain, midbrain, cerebellum, hindbrain, and olfactory bulbs. The dissected parts were flash-frozen on dry ice and stored at -80o C. Samples were coded by treatment: vehicle-treated mice (n=8) and OT-treated mice (n=12).
Sample Type:	Brain

Treatment:

Treatment ID:	TR000445
Treatment Summary:	BALB/cByJ male mice (4-5 weeks in age; Jackson Laboratory, Bar Harbor, ME) were given four treatments of either vehicle or OT (1.0 mg/kg; IP) across 8 days, with at least 48 hours between each injection. Mice were evaluated in a 3-chamber choice test for social preference 24 hr after the final injection.

Sample Preparation:

Sampleprep ID:	SP000438
Sampleprep Summary:	The NMR samples were used for the neurotransmitter analysis after NMR data acquisition. These samples were lyophilized overnight followed by reconstitution in 50 µL 95:5 methanol:water. Following a final centrifugation, extracts were transferred to vials for analysis by injection (20 µL) onto the Thermo Scientific (TS) 3000 series U-HPLC system. Compound separation was achieved on a Thermo Scientific Hypersil Gold, 200 x 2.1 mm column, and 1.9 µm particle size with an isocratic flow rate of 0.400 mL/min with a column temperature of 30°C. Simultaneous detection of neurotransmitters was achieved by the TS 5600A 16 channel coulometric array ECD with coulometric cells set at incremental potentials ranging from -150 mV to 900 mV. A Standard Mix containing 14 target compounds at known concentrations was analyzed just prior to each batch to confirm the retention time and elution channel of each compound. Additionally, the mix was used as an external standard to semi-quantitate any targets found in the extracts.

Sampleprep ID:

SP000438

Sampleprep Summary:

The NMR samples were used for the neurotransmitter analysis after NMR data acquisition. These samples were lyophilized overnight followed by reconstitution in 50 µL 95:5 methanol:water. Following a final centrifugation, extracts were transferred to vials for analysis by injection (20 µL) onto the Thermo Scientific (TS) 3000 series U-HPLC system. Compound separation was achieved on a Thermo Scientific Hypersil Gold, 200 x 2.1 mm column, and 1.9 µm particle size with an isocratic flow rate of 0.400 mL/min with a column temperature of 30°C. Simultaneous detection of neurotransmitters was achieved by the TS 5600A 16 channel coulometric array ECD with coulometric cells set at incremental potentials ranging from -150 mV to 900 mV. A Standard Mix containing 14 target compounds at known concentrations was analyzed just prior to each batch to confirm the retention time and elution channel of each compound. Additionally, the mix was used as an external standard to semi-quantitate any targets found in the extracts.

Analysis:

Analysis ID:	AN000650
Analysis Type:	NMR
Num Factors:	11
Num Metabolites:	14
Units:	ng

NMR:

NMR ID:	NM000072
Analysis ID:	AN000650
Instrument Name:	Thermo Scientific 5600A 16 channel coulometric array ECD
Instrument Type:	Other
NMR Experiment Type:	Other